New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
18:10 EDTRHHBYRoche unit Genentech's Perjeta shows extended survival in breast cancer patients
Genentech, a member of the Roche Group (RHHBY), announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta, Herceptin and docetaxel chemotherapy significantly extended the overall survival of people with previously untreated HER2-positive metastatic breast cancer, compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34% for people who received Perjeta, Herceptin and chemotherapy, compared to those who received Herceptin and chemotherapy. At the time of the analysis, median overall survival had not yet been reached in people receiving the Perjeta combination, as more than half of these people continued to survive. Median overall survival was 37.6 months for people who received Herceptin and chemotherapy. Based on these data, people receiving Herceptin and chemotherapy in CLEOPATRA have been offered the option to receive Perjeta. No new safety signals were observed in the study.
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
07:39 EDTRHHBYAbbVie says venetoclax granted Breakthrough Therapy Designation by FDA
Subscribe for More Information
May 5, 2015
16:15 EDTRHHBYPacific Biosciences achieves second development milestone under Roche pact
Subscribe for More Information
May 4, 2015
07:26 EDTRHHBYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
May 1, 2015
07:43 EDTRHHBYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 27, 2015
06:19 EDTRHHBYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 22, 2015
05:27 EDTRHHBYRoche sees FY15 core EPS to grow ahead of sales at constant exchange rates
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:27 EDTRHHBYRoche reports Q1 group sales CHF 11.83B vs. CHF 11.50B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use